Kazia Therapeutics Advances Paxalisib for HER2-Positive Breast Cancer Treatment

Kazia Therapeutics Expands Therapeutic Potential of Paxalisib in HER2-Positive Breast Cancer

Kazia Therapeutics Limited, an oncology-focused drug development company, recently unveils promising data from a research collaboration led by Professor Sudha Rao at QIMR Berghofer. This study explores the effects of paxalisib, Kazia’s investigational PI3K–mTOR inhibitor, on patients suffering from Stage IV HER2-positive metastatic breast cancer (mBC). The findings reveal that paxalisib monotherapy significantly reduces single circulating tumor cells (CTCs) and achieves a complete 100% disruption of CTC clusters. These clusters are critical biomarkers indicative of disease aggression and the potential for metastasis, making the results particularly noteworthy.

HER2-positive breast cancer, which accounts for 15-20% of breast cancer cases, represents a significant treatment challenge due to its propensity for resistance and recurrence even after HER2-targeted therapies. The study’s results indicate that paxalisib may represent a new therapeutic option for this difficult-to-treat patient population, especially given that existing immunotherapy approaches have yielded limited success. By demonstrating the ability to disrupt CTC clusters and reduce CTCs, the research suggests that paxalisib could play a vital role in managing metastatic disease in HER2-positive breast cancer patients.

Dr. John Friend, CEO of Kazia Therapeutics, underscores the importance of these findings, noting that they expand paxalisib's potential therapeutic applications beyond triple-negative breast cancer to include HER2-positive subtypes. This research aligns with Kazia’s ongoing Phase 1b trial, which has already indicated significant reductions in CTCs and clusters in patients with Stage IV triple-negative breast cancer. The company plans to present comprehensive datasets on metastatic signatures at a global oncology meeting in 2025, reflecting its commitment to addressing the high unmet needs in advanced breast cancer treatment.

In addition to these groundbreaking findings, Kazia Therapeutics continues to focus on precision medicine, utilizing biomarkers to better monitor metastatic burden and guide treatment decisions. The implications of this research could reshape the therapeutic landscape for HER2-positive metastatic breast cancer, offering hope to patients who currently face limited options.

Kazia's proactive approach in advancing paxalisib as a viable treatment alternative signifies a notable step forward in the oncology field, particularly in addressing the complexities of HER2-positive breast cancer. As the company prepares for further presentations and studies, the oncology community remains optimistic about the potential impact of these developments on patient outcomes.